Threshold: WHO-CHOICE proxy 1x PDB Rp 75jt/QALY; 3x PDB Rp 225jt/QALY; InaHTAC may apply different decision rules.
Both esomeprazole and omeprazole are BPOM-registered and available in Indonesia; omeprazole is the generic Fornas/JKN backbone PPI, while esomeprazole (Nexium and generics such as Esomeprazole Etercon) is marketed at a substantial price premium.
NICE CG184's lowest-acquisition-cost-PPI recommendation maps directly onto an Indonesian Fornas stewardship stance: omeprazole first-line, esomeprazole reserved for persistent/severe (LA C/D) disease.
The base-case result is dominated by the esomeprazole-minus-omeprazole price gap; the price-parity scenario is the single most decision-relevant analysis and is included in scenario_config alongside a branded-price scenario.
Budget impact is driven almost entirely by drug-acquisition difference because healing and complication differences are marginal; even modest penetration of a premium PPI in a high-prevalence condition produces a large incremental JKN cost.
Reviewers should verify current Fornas listing/restriction status for esomeprazole and obtain validated INAPROC/e-katalog LKPP unit prices before any policy interpretation.